Clinical TrialJul 27, 2026, 07:31 AM
Eikon Therapeutics Doses First Patient in Phase 2/3 NSCLC Trial
AI Summary
Eikon Therapeutics announced the dosing of the first patient in TeLuRide-008, a Phase 2/3 registrational study for EIK1001. This study evaluates EIK1001 in combination with pembrolizumab and chemotherapy as a first-line therapy for treatment-naïve patients with Stage 4 Non-Small Cell Lung Cancer (NSCLC). EIK1001 is designed to enhance immune response, and this marks a significant milestone as the company advances its pipeline to address unmet medical needs in oncology.
Key Highlights
- First patient dosed in TeLuRide-008, a Phase 2/3 registrational study for EIK1001.
- TeLuRide-008 evaluates EIK1001 with pembrolizumab and chemotherapy for Stage 4 NSCLC.
- Study targets first-line, treatment-naïve non-small cell lung cancer patients.
- EIK1001 is an investigational dual-agonist of Toll-like receptors 7 and 8.
- TeLuRide-008 is the second registrational Phase 2/3 trial for EIK1001.
Price Impact
More from EIKN